Free Trial
Farzin Haque

Farzin Haque Analyst Performance

Senior Vice President, Biotechnology Equity Research Analyst at Jefferies Financial Group

Farzin Haque is a stock analyst at Jefferies Financial Group focused in the medical sector, covering 3 publicly traded companies. Over the past year, Farzin Haque has issued 7 stock ratings, including strong buy and buy recommendations. While full access to Farzin Haque's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Farzin Haque's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
7 Last 0 Years
Buy Recommendations
100.00% 7 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy28.6%2 ratings
Buy71.4%5 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Farzin Haque at Jefferies Financial Group, the majority (71.4%) have been Buy recommendations, followed by 28.6% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
2 companies
NYSE
33.3% of companies on NYSE
1 company

Farzin Haque, an analyst at Jefferies Financial Group, currently covers 3 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
66.7%
Manufacturing
1 company
33.3%

Farzin Haque of Jefferies Financial Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
33.3%
MED - DRUGS
1 company
33.3%
MED - BIOMED/GENE
1 company
33.3%

Farzin Haque's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
4/30/2026Upgrade$14.33Strong-Buy
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3/30/2026Initiated Coverage$14.48$50.00Buy
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3/29/2026Upgrade$14.70Strong-Buy
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
12/22/2025Initiated Coverage$4.35$9.00Buy
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
12/22/2025Initiated Coverage$4.46$9.00Buy
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/30/2025Initiated Coverage$3.22$10.00Buy
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
9/30/2025Initiated Coverage$3.70$10.00Buy